# Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

> **NCT02970669** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 140 (actual)

## Conditions studied

- Heart Failure, Reduced Ejection Fraction

## Interventions

- **DRUG:** sacubitril/valsartan (LCZ696)
- **DRUG:** enalapril
- **DRUG:** matching placebo sacubitril/valsartan (LCZ696)
- **DRUG:** matching placebo enalapril

## Key facts

- **NCT ID:** NCT02970669
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-16
- **Primary completion:** 2018-03-19
- **Final completion:** 2018-03-19
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2021-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970669, "Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02970669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*